Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Array BioPharma has selected ASLAN Pharmaceuticals for the development of its HER2 / EGFR inhibitor - ARRY-543.
Subscribe to our email newsletter
ARRY-543 is currently entering Phase 2 development for solid tumors.
As per the terms of the agreement, ASLAN Pharma will provide funding and will also be responsible for the development of ARRY-543 through proof of concept for patents with gastric cancer, through a development program conducted in Asia.
ASLAN Pharma will identify a global partner for Phase 3 development and commercialization.
It will initiate phase 2 trials in gastric cancer and other tumor types.
Array CEO Robert Conway said their partnership with ASLAN provides a great opportunity to fund and advance the development of ARRY-543.
"ASLAN’s development strategy of leveraging Asia to conduct clinical development is particularly compelling for ARRY-543 due to the high prevalence of patients with gastric cancer in Asia," Conway said.